PAB chart, page-283

Among the biotechs on the ASX, PAB is one of kind with huge potential. Its flagship asset PAT-DX1
- is a great DDR-based anticancer antibody (potentially much better than those hot PARPi small molecules)
- is able to localise to and penetrate into a range of tumor cells
- can work synergistically with PARP inhibitor to drastically improve efficacy
- can cross Blood Brain Barrier and kill brain cancer cells as single agent (and in combination with PARPi? awaiting the answer in next ann)
- can use nanoparticles as vehicles for cancer drug delivery with excellent tumor specificity
- can potentially be engineered to be bispecific antibodies for various intracellular targets
- ... etc

With the most advantageous combination, PAT-DX1 seems to have seized the technical commanding point in monoclonal antibody field and made itself stand out among the crowd.

Big pharmas are always looking for novel therapies particularly those that can be combined with existing treatments on the market in a safe and effective way. At present it should be the case that there is significant interest in PAT-DX1.

As such, Patrys is now onto something big and in a good position to engage in detailed discussions with prospective partners.

Below are the excerpts from the Internet.

"A clear picture emerges of where Big Pharma is currently spending their deal money. Stand-out areas are platform technologies such as Antibody Drug Conjugates (ADCs) and the new approach tackling checkpoint inhibitors. As such, the majority of Big Pharma companies are following antibody-based oncology therapies."

"It’s a fairy tale for IFM to be swept up in a blockbuster deal (2.3B) just a year after a series A and with such early-stage candidates. Of course, BMS is no stranger to biotech buyouts. Gaining rights to early-stage assets gives the licensee more flexibility to shape its development. Furthermore, early-stage assets often comprise of "platforms" which could deliver multiple new drugs. Increased competition for early stage assets appears to be driving total deal values higher in this sector."